Fidanacogene Elaparvovec Side Effects
Applies to fidanacogene elaparvovec: intravenous suspension.
Important warnings
This medicine can cause some serious health issues
This medicine may not work for every person who receives it.
Talk to your doctor if you have any questions.
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Some side effects may occur during or right after the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, unusual bleeding, or swelling in your face.
Common side effects may include:
-
abnormal liver tests.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For healthcare professionals
Applies to fidanacogene elaparvovec: intravenous suspension.
General adverse events
The most common adverse reaction was an increase in transaminases.[Ref]
Hepatic
- Very common (10% or more): Increased transaminases (up to 53.3%)[Ref]
Increased transaminases included increased ALT, increased AST, increased hepatic enzyme, abnormal hepatic function, abnormal liver function tests, and increased transaminases.[Ref]
References
1. (2024) "Product Information. Beqvez (upto 75 kg) (fidanacogene elaparvovec)." Pfizer U.S. Pharmaceuticals Group
More about fidanacogene elaparvovec
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: miscellaneous coagulation modifiers
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Fidanacogene elaparvovec side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.